http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2607879-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 |
| filingDate | 2013-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a365f72b571cbf1900e7a9d6cfc67a0c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb522f685318363b81d7778ac7672f5d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fb19fbb603dd614edc0f5a3daf02ecf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ff496b1317a05f24d45a5b67371451a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebc3f91f5f944d8755cda286978c22a1 |
| publicationDate | 2017-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2607879-T3 |
| titleOfInvention | Quinoline Antibacterial Derivatives |
| abstract | A compound of formula (Ia) or (Ib): ** Formula ** including any stereochemically isomeric form thereof, wherein p is an integer equal to 1, 2, 3 or 4; n is an integer equal to 10 or 1; with the proviso that if n is 2 then both R5 substituents are attached to the same carbon atom of the piperidine residue; R1 is hydrogen, cyano, cyanoC1-6alkyl, formyl, carboxyl, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, polyhaloalkylC1-6alkyl, hydroxy, C1-6alkyloxyC1-6alkyloxyC1-6alkyloxy 6, C1-6alkylthioC1-6alkyl, -C> = N-OR11, amino, mono- or di (C1-6alkyl) amino, aminoC1-6alkyl, mono- or di (C1-6alkyl aminoC1-6alkyl, C1-6alkylcarbonylaminoalkylC1- 6, R9bR10bN-C (> = O) -, arylalkylC1-6, arylcarbonyl, R9aR10aNalkylC1-6, di (aryl) alkylC1-6, aryl, cycloalkylC3-6, R9aR10aN-, R9aR10aN-C (> O) - -4-S (> = O) 2-, or Het; R2 is hydrogen, C1-6alkyloxy, aryl, aryloxy hydroxy, mercapto, C1-6alkyloxyC1-6alkyloxy, C1-6alkylthio, mono- or ** Formula ** di (C1-6alkyl) amino, amino, pyrrolidine or a radical of the formula in where Y is CH2, O, S, NH or NalkylC1-6; R3 is hydrogen, halo, C1-6alkyl, aryl or Het; R4 is aryl1 or Het; R5 is aryl, arylaC1-6alkyl, C3-6cycloalkyl, cycloalkylC3-6alkylC1-6, Het, Het-C1-6alkyl, C1-6alkyl, hydroxyalkylC1-6alkyl, aminoC1-6alkyl, mono- or di (C1-4alkyl) -alkylC1-6. , aryl-NH-C1-6alkyl, Het-NH-C1-6alkyl, C2-6alkenyl or halo; R6 is hydrogen, C1-6alkyl, arylalkylC1-6, Het1, Het1C1-6alkyl or -C (> = NH) -NH2; R7 is hydrogen or C1-6alkyl; R8 is oxo; or R7 and R8 together form the radical -CH> = CH-N> =; R9a and R10a together with the nitrogen atom to which they are attached form a radical selected from the group consisting of pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 4-thiomorpholinyl, 2,3-dihydroisoindole-1-yl, thiazolidin-3-yl, 1,2,3,6-tetrahydropyridyl, hexahydro-1H-azepinyl, hexahydro-1H-1,4-diazepinyl, hexahydro-1,4-oxazepinyl, 1,2,3,4-tetrahydroisoquinolin-2-yl, pyrrolinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, 2-imidazolinyl, 2-pyrazolinyl, imidazolyl, pyrazolyl, triazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl, each radical being optionally substituted with 1, 2, 3 or 4 substituents, each substituent being independently selected C1-6alkyl, polyhaloalkylC1-6, halo, arylalkylC1-6, hydroxy, alkyloxyC1-6, amino, mono- or di (C1-6alkyl) amino, alkylthioC1-6alkylthioC1-6alkyl, aryl, pyridyl or pyrimidinyl; R9b and R10b each independently represent hydrogen, C1-6alkyl, aryl or Het; R11 is hydrogen or C1-6alkyl; aryl is a homocycle selected from phenyl, naphthyl, acenaphthyl, or tetrahydronaphthyl, each being optionally substituted with 1, 2, or 3 substituents, each substituent independently being selected from hydroxy, C 1-6 hydroxyalkyl, halo, cyano, C 1-6 cyanoalkyl, nitro, amino, mono- or di (C1-6alkyl) amino, C1-6alkyl, C2-6alkenyl optionally substituted with phenyl, polyhaloalkylC1-6, alkyloxyC1-6alkylC1-6, polyhaloalkyloxyC1-6, carboxyl, alkyloxyC1-6carbonyl, or mono- or di (C1-6alkyl) aminocarbonyl; aryl1 is a homocycle selected from phenyl, naphthyl, acenaphthyl, or tetrahydronaphthyl, each being optionally substituted with 1, 2, or 3 substituents, each substituent independently being selected from hydroxy, C 1-6 hydroxyalkyl, halo, cyano, C 1-6 cyanoalkyl, nitro, amino, mono- or di (C1-6alkyl) amino, C1-6alkyl, polyhaloalkylC1-6, alkyloxyC1-6, alkyloxyC1-6alkylC1-6, alkylthioC1-6, polyhaloalkyloxyC1-6, carboxyl, alkyloxyC1-6carbonyl, aminocarbonyl, Het, di (C1-6alkyl) aminocarbonyl, or C1-4alkyl-S (> = O) 2-; Het is a monocyclic heterocycle selected from N-phenoxypiperidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl 4-, pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl; or a bicyclic heterocycle selected from quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl, benzothienyl, 2,3-dihydrobenzo [1,4] dioxinyl or benzo [1,3] dioxolyl; each monocyclic and bicyclic heterocycle being optionally substituted with 1, 2 or 3 substituents, each substituent independently being selected from halo, hydroxy, C1-6alkyl or C1-6alkyloxy; Het1 is a monocyclic saturated heterocycle selected from pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, 4-thiomorpholinyl, imidazolidinyl, pyrazolidinyl; each saturated monocyclic heterocycle being optionally substituted with C1-6alkyl or arylalkylC1-6; an N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. |
| priorityDate | 2012-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 490.